My bibliography
Save this item
Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Arndt R. Reichert & Magdalena A. Stroka, 2018.
"Nursing home prices and quality of care — Evidence from administrative data,"
Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 129-140, January.
- Reichert, Arndt R. & Stroka, Magdalena A., 2014. "Nursing Home Prices and Quality of Care - Evidence from Administrative Data," Ruhr Economic Papers 470, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
- Joosse, Iris R. & Tordrup, David & Glanville, Julie & Mantel-Teeuwisse, Aukje K. & van den Ham, Hendrika A., 2023. "A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain," Health Policy, Elsevier, vol. 138(C).
- Liu, Ya-Ming & Cheng, Jur-Shan, 2012. "Determinants of generic entry in the regulated Taiwanese prescription drug market," Health Policy, Elsevier, vol. 108(2), pages 228-235.
- Daniel Burkhard & Christian P. R. Schmid & Kaspar Wüthrich, 2019.
"Financial incentives and physician prescription behavior: Evidence from dispensing regulations,"
Health Economics, John Wiley & Sons, Ltd., vol. 28(9), pages 1114-1129, September.
- Daniel Burkhard & Christian Schmid & Kaspar W thrich, 2015. "Financial incentives and physician prescription behavior: Evidence from dispensing regulations," Diskussionsschriften dp1511, Universitaet Bern, Departement Volkswirtschaft.
- Burkhard, D.; & Schmid, C.P.R.; & Wüthrich, K.;, 2018. "Financial incentives and physician prescription behavior.Evidence from dispensing regulations," Health, Econometrics and Data Group (HEDG) Working Papers 18/17, HEDG, c/o Department of Economics, University of York.
- Gerald J. Pruckner & Thomas Schober, 2018.
"Hospitals and the generic versus brand‐name prescription decision in the outpatient sector,"
Health Economics, John Wiley & Sons, Ltd., vol. 27(8), pages 1264-1283, August.
- Gerald J. Pruckner & Thomas Schober, 2016. "Hospitals and the generic versus brand-name prescription decision in the outpatient sector," CDL Aging, Health, Labor working papers 2016-05, The Christian Doppler (CD) Laboratory Aging, Health, and the Labor Market, Johannes Kepler University Linz, Austria.
- Gerald J. Pruckner & Thomas Schober, 2016. "Hospitals and the generic versus brand-name prescription decision in the outpatient sector," Economics working papers 2016-11, Department of Economics, Johannes Kepler University Linz, Austria.
- Claudio Deiana & Ludovica Giua & Roberto Nisticò, 2019.
"The Economics Behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US,"
CSEF Working Papers
525, Centre for Studies in Economics and Finance (CSEF), University of Naples, Italy, revised 13 May 2019.
- Deiana, Claudio & Giua, Ludovica & Nistico, Roberto, 2019. "The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US," IZA Discussion Papers 12872, Institute of Labor Economics (IZA).
- Zhou, Cuihua & Hao, Yifei & Lan, Yanfei & Li, Weifeng, 2023. "To introduce or not? Strategic analysis of hospital operations with telemedicine," European Journal of Operational Research, Elsevier, vol. 304(1), pages 292-307.
- Kim, Seung Ju & Han, Kyu-Tae & Kim, Sun Jung & Park, Eun-Cheol & Park, Hye Ki, 2016. "Impact of a diagnosis-related group payment system on cesarean section in Korea," Health Policy, Elsevier, vol. 120(6), pages 596-603.
- Rachet-Jacquet, Laurie & Toulemon, Léa & Rochaix, Lise, 2021.
"Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List,"
Health Policy, Elsevier, vol. 125(7), pages 923-929.
- Laurie Rachet-Jacquet & Léa Toulemon & Lise Rochaix, 2021. "Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List," Post-Print halshs-03238834, HAL.
- Laurie Rachet-Jacquet & Léa Toulemon & Lise Rochaix, 2021. "Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List," PSE-Ecole d'économie de Paris (Postprint) halshs-03238834, HAL.
- Laurie Rachet-Jacquet & Léa Toulemon & Lise Rochaix, 2021. "Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List," Institut des Politiques Publiques halshs-03238834, HAL.
- Alexander Ahammer & Ivan Zilic, 2017.
"Do Financial Incentives Alter Physician Prescription Behavior? Evidence from Random Patient-GP Allocations,"
Working Papers
1701, The Institute of Economics, Zagreb.
- Alexander Ahammer & Ivan Zilic, 2017. "Do Financial Incentives Alter Physician Prescription Behavior? Evidence From Random Patient-GP Allocations," CDL Aging, Health, Labor working papers 2017-02, The Christian Doppler (CD) Laboratory Aging, Health, and the Labor Market, Johannes Kepler University Linz, Austria.
- Alexander Ahammer & Ivan Zilic, 2017. "Do Financial Incentives Alter Physician Prescription Behavior? Evidence From Random Patient-GP Allocations," Economics working papers 2017-02, Department of Economics, Johannes Kepler University Linz, Austria.
- Tianyan Hu & Sandra L. Decker & Shin-Yi Chou, 2014. "The Impact of Health Insurance Expansion on Physician Treatment Choice: Medicare Part D and Physician Prescribing," NBER Working Papers 20708, National Bureau of Economic Research, Inc.
- Skipper, Niels & Vejlin, Rune, 2015.
"Determinants of generic vs. brand drug choice: Evidence from population-wide Danish data,"
Social Science & Medicine, Elsevier, vol. 130(C), pages 204-215.
- Niels Skipper & Rune Vejlin, 2013. "Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data," Economics Working Papers 2013-05, Department of Economics and Business Economics, Aarhus University.
- Babar, Z.U.D. & Kan, S.W. & Scahill, S., 2014. "Interventions promoting the acceptance and uptake of generic medicines: A narrative review of the literature," Health Policy, Elsevier, vol. 117(3), pages 285-296.
- Toshiaki Iizuka, 2012. "Physician Agency and Adoption of Generic Pharmaceuticals," American Economic Review, American Economic Association, vol. 102(6), pages 2826-2858, October.
- Claudio Deiana & Ludovica Giua & Roberto Nisticò, 2024.
"Opium Price Shocks and Prescription Opioids in the USA,"
Oxford Bulletin of Economics and Statistics, Department of Economics, University of Oxford, vol. 86(3), pages 449-484, June.
- Deiana, C. & Giua, L. & Nisticò, R., 2020. "Opium Price Shocks and Prescription Opioids in the US," Health, Econometrics and Data Group (HEDG) Working Papers 20/23, HEDG, c/o Department of Economics, University of York.
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2014.
"Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark,"
Journal of Health Economics, Elsevier, vol. 36(C), pages 174-187.
- Ulrich Kaiser & Susan J. Mendez & Thomas Rønde, 2010. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," CIE Discussion Papers 2010-01, University of Copenhagen. Department of Economics. Centre for Industrial Economics.
- Kaiser, Ulrich & Méndez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," IZA Discussion Papers 7248, Institute of Labor Economics (IZA).
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas, 2010. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," ZEW Discussion Papers 10-062, ZEW - Leibniz Centre for European Economic Research.
- Ulrich Kaiser & Susan J. Méndez & Thomas Rønde & Hannes Ullrich, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," Working Papers 330, University of Zurich, Department of Business Administration (IBW).
- Kaiser, Ulrich & Méndez, Susan & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79937, Verein für Socialpolitik / German Economic Association.
- Arndt R. Reicher & Magdalena Stroka, 2014. "Nursing Home Prices and Quality of Care - Evidence from Administrative Data," Ruhr Economic Papers 0470, Rheinisch-Westfälisches Institut für Wirtschaftsforschung, Ruhr-Universität Bochum, Universität Dortmund, Universität Duisburg-Essen.
- Hjalmarsson, Linn & Schmid, Christian P.R. & Schreiner, Nicolas, 2024. "A Prescription for Knowledge: Patient Information and Generic Substitution," Working papers 2024/05, Faculty of Business and Economics - University of Basel.
- Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune, 2013.
"Margins and market shares: Pharmacy incentives for generic substitution,"
European Economic Review, Elsevier, vol. 61(C), pages 116-131.
- Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune, 2010. "Margins and Market Shares: Pharmacy Incentives for Generic Substitution," Discussion Paper Series in Economics 18/2010, Norwegian School of Economics, Department of Economics.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2012. "Margins and Market Shares: Pharmacy Incentives for Generic Substitution," CESifo Working Paper Series 4055, CESifo.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Margins and Market Shares:Pharmacy Incentives for Generic Substitution," NIPE Working Papers 20/2010, NIPE - Universidade do Minho.
- Müller, Tobias & Schmid, Christian & Gerfin, Michael, 2023.
"Rents for Pills: Financial incentives and physician behavior,"
Journal of Health Economics, Elsevier, vol. 87(C).
- Gerfin, Michael & Müller, Tobias & Schmid, Christian, 2022. "Rents for Pills: Financial Incentives and Physician Behavior," VfS Annual Conference 2022 (Basel): Big Data in Economics 264037, Verein für Socialpolitik / German Economic Association.
- Shin‐Yi Chou & James A. Dearden & Mary E. Deily & Hsien‐Ming Lien, 2020. "Provider responses to a global budgeting system: The case of drug expenditures in Taiwan hospitals," Health Economics, John Wiley & Sons, Ltd., vol. 29(10), pages 1270-1278, October.
- Olivia Bodnar & Hugh Gravelle & Nils Gutacker & Annika Herr, 2024.
"Financial incentives and prescribing behavior in primary care,"
Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 696-713, April.
- Olivia Bodnar & Hugh Gravelle & Nils Gutacker & Annika Herr, 2021. "Financial incentives and prescribing behaviour in primary care," Working Papers 181cherp, Centre for Health Economics, University of York.
- Boris Kaiser, Christian Schmid, 2013.
"Does Physician Dispensing Increase Drug Expenditures?,"
Diskussionsschriften
credresearchpaper02, Universitaet Bern, Departement Volkswirtschaft - CRED.
- Boris Kaiser & Christian Schmid, 2013. "Does Physician Dispensing Increase Drug Expenditures?," Diskussionsschriften dp1303, Universitaet Bern, Departement Volkswirtschaft.
- Newham, Melissa & Valente, Marica, 2024.
"The cost of influence: How gifts to physicians shape prescriptions and drug costs,"
Journal of Health Economics, Elsevier, vol. 95(C).
- Melissa Newham & Marica Valente, 2022. "The Cost of Influence: How Gifts to Physicians Shape Prescriptions and Drug Costs," Papers 2203.01778, arXiv.org, revised Apr 2023.
- Melissa Newham & Marica Valente, 2023. "The Cost of Influence:How Gifts to Physicians Shape Prescriptions and Drug Costs," Working Papers 2023-03, Faculty of Economics and Statistics, Universität Innsbruck.
- Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: Evidence from South African doctors," Journal of Development Economics, Elsevier, vol. 158(C).
- Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: evidence from South African doctors," LSE Research Online Documents on Economics 115383, London School of Economics and Political Science, LSE Library.
- Ya‐Ming Liu & Chee‐Ruey Hsieh, 2012. "New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan," Health Economics, John Wiley & Sons, Ltd., vol. 21(5), pages 496-513, May.
- Makoto Kakinaka & Ryuta Kato, 2013.
"Regulated medical fee schedule of the Japanese health care system,"
International Journal of Health Economics and Management, Springer, vol. 13(3), pages 301-317, December.
- Makoto Kakinaka & Ryuta Ray Kato, 2011. "Regulated Medical Fee Schedule of the Japanese Health Care System," Working Papers EMS_2011_13, Research Institute, International University of Japan.
- Filippini, M. & Heimsch, F. & Masiero, G., 2014.
"Antibiotic consumption and the role of dispensing physicians,"
Regional Science and Urban Economics, Elsevier, vol. 49(C), pages 242-251.
- Massimo Filippini & Fabian Heimsch & Giuliano Masiero, 2013. "Antibiotic consumption and the role of dispensing physicians," CEPRA working paper 1302, USI Università della Svizzera italiana.
- Liu, Ya-Ming & Yang, Yea-Huei Kao & Hsieh, Chee-Ruey, 2012. "Regulation and competition in the Taiwanese pharmaceutical market under national health insurance," Journal of Health Economics, Elsevier, vol. 31(3), pages 471-483.
- Meng‐Chi Tang, 2023. "A structural analysis of physician agency and pharmaceutical demand," Health Economics, John Wiley & Sons, Ltd., vol. 32(7), pages 1453-1477, July.
- Boris Kaiser & Christian Schmid, 2016. "Does Physician Dispensing Increase Drug Expenditures? Empirical Evidence from Switzerland," Health Economics, John Wiley & Sons, Ltd., vol. 25(1), pages 71-90, January.
- Stacherl, Barbara & Renner, Anna-Theresa & Weber, Daniela, 2023. "Financial incentives and antibiotic prescribing patterns: Evidence from dispensing physicians in a public healthcare system," Social Science & Medicine, Elsevier, vol. 321(C).
- Crea, Giovanni & Galizzi, Matteo M. & Linnosmaa, Ismo & Miraldo, Marisa, 2019.
"Physician altruism and moral hazard: (no) Evidence from Finnish national prescriptions data,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 153-169.
- Crea, Giovanni & Galizzi, Matteo M. & Linnosmaa, Ismo & Miraldo, Marisa, 2019. "Physician altruism and moral hazard: (no) evidence from Finnish national prescriptions data," LSE Research Online Documents on Economics 100301, London School of Economics and Political Science, LSE Library.
- Maurus Rischatsch & Maria Trottmann & Peter Zweifel, 2013. "Generic substitution, financial interests, and imperfect agency," International Journal of Health Economics and Management, Springer, vol. 13(2), pages 115-138, June.
- Liu, Ya-Ming & Kao Yang, Yea-Huei & Hsieh, Chee-Ruey, 2011. "The determinants of the adoption of pharmaceutical innovation: Evidence from Taiwan," Social Science & Medicine, Elsevier, vol. 72(6), pages 919-927, March.
- Magno, Cielo & Guzman, Ricardo Rafael S., 2019. "Drug price sensitivity among physicians in a developing healthcare system: Evidence from the Philippine market for statins and beta blockers," Economic Analysis and Policy, Elsevier, vol. 62(C), pages 268-279.
- Costa-Font, Joan & Rudisill, Caroline & Tan, Stefanie, 2014. "Brand loyalty, patients and limited generic medicines uptake," Health Policy, Elsevier, vol. 116(2), pages 224-233.
- Fu, Hongqiao & Li, Ling & Yip, Winnie, 2018. "Intended and unintended impacts of price changes for drugs and medical services: Evidence from China," Social Science & Medicine, Elsevier, vol. 211(C), pages 114-122.
- repec:zbw:rwirep:0470 is not listed on IDEAS
- Meng-Chi Tang & Yi-Nong Wu, 2020. "Medical providers as double agents in a universal health care system: evidence from generic pharmaceutical adoption in Taiwan," Empirical Economics, Springer, vol. 59(1), pages 169-203, July.
- Lai, Yi & Fu, Hongqiao & Li, Ling & Yip, Winnie, 2022. "Hospital response to a case-based payment scheme under regional global budget: The case of Guangzhou in China," Social Science & Medicine, Elsevier, vol. 292(C).
- Granlund, David & Sundström, David, 2018. "Physicians prescribing originals causes welfare losses," Economics Letters, Elsevier, vol. 170(C), pages 143-146.
- Andrew Epstein & Scott Johnson, 2012. "Physician response to financial incentives when choosing drugs to treat breast cancer," International Journal of Health Economics and Management, Springer, vol. 12(4), pages 285-302, December.